Safety of Rush Immunotherapy with Allergen Products of Peking Union Medical College Hospital in Allergic Rhinitis and Asthma
10.11969/j.issn.1673-548X.2025.03.006
- VernacularTitle:协和变应原制剂冲击免疫治疗应用于过敏性鼻炎和哮喘的安全性
- Author:
Yingyang XU
1
;
Songjiang XU
;
Huishuang ZHENG
Author Information
1. 100730 中国医学科学院/北京协和医学院北京协和医院变态(过敏)反应科、过敏性疾病精准诊疗研究北京市重点实验室、国家免疫性疾病临床医学研究中心
- Publication Type:Journal Article
- Keywords:
Rush immunotherapy;
Safety;
Allergic rhinitis;
Asthma;
Risk factor
- From:
Journal of Medical Research
2025;54(3):23-27,33
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety of rush immunotherapy(RIT)with allergen products of Peking Union Medical College Hospital in allergic rhinitis with/without asthma.Methods One hundred and eight patients with allergic rhinitis with/without asthma who received RIT with allergen products of Peking Union Medical College Hospital were retrospectively analyzed.The occurrence characteris-tics of adverse reactions and their risk factors of RIT were summarized.Results A total of 840 injections were administered to 108 pa-tients.Local reactions occurred in 57(52.8％)patients and 57(6.8％)injections.Systemic reactions were observed in 3(2.8％)pa-tients and 3(0.4％)injections.One of systemic reactions was grade Ⅱ and the other two were grade Ⅲ.The incidence of adverse reac-tions in patients using pollen RIT was significantly higher than those using house dust mite or mold(48.1％vs 4.6％,P=0.001).Among 79 patients receiving pollen RIT,the incidence of local reactions was higher in patients who initiated RIT during pollen season than those out of pollen season(54.4％vs 11.4％,P=0.001).The skin test strength of pollen was defined as the sum of"+"in pollen pollen allergenic skin test.Greater strength of tree(P＜0.05,OR=1.631)and weed(P＜0.05,OR=1.334)pollen seemed to pro-mote local reactions.Conclusion RIT with single or multiple allergens significantly reduces the build-up phase and frequency of hospi-tal visits,and has low occurrence of systemic reactions.Thus,RIT can improve the compliance for allergen immunotherapy.
